Write For Us

'Second Opinion,' Episode 7: The Third Wave

Sponsored Post Vitamin D2 Canada Persia
115 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

ava
Published
"Second Opinion," a new discussion series produced by L.A. Times Studios in conjunction
with the Los Angeles Times newsroom, takes you to the forefront of medical research and conversations about health, science and technology.

In our seventh episode, Los Angeles Times Executive Chairman Dr. Patrick Soon-Shiong speaks with Dr. Adam Brufsky, an oncologist and professor at the University of Pittsburgh School of Medicine, about this fall's resurgence of the coronavirus. The discussion also covers how the various vaccine candidates in Phase 3 trials in the United States work,
and how daily life might change once a vaccine is introduced to the public.

Though he specializes in breast cancer, Brufsky sees parallels between the behavior of
cancer and COVID-19 and has published nine academic papers on the novel coronavirus. Soon-Shiong is a surgeon and scientist specializing in the immune system and infectious disease. In mid-October, Soon-Shiong's company, ImmunityBio, received permission from
the Food and Drug Administration to begin Phase 1 trials of its COVID-19 vaccine candidate.

Dr. Adam Brufsky is a professor at University of Pittsburgh School of Medicine and an associate chief of the hematology-oncology division at University of Pittsburgh Medical
Center. Brufsky specializes in metastatic breast cancer and leads research studies funded by the National Institutes of Health, the Susan G. Komen Foundation and the U.S. Army Breast Cancer Research Program. In addition to his medical degree, he has a doctorate in developmental biology and molecular genetics.

Dr. Patrick Soon-Shiong, executive chairman of the Los Angeles Times, is a surgeon and scientist who has spent his career studying the human immune system to fight cancer and infectious diseases. He is the chairman and chief executive of NantWorks, and the owner of or investor in a number of companies, including ImmunityBio and NantKwest, which are currently researching immunotherapies for COVID-19.

SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription

LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
Category
U.S. & Canada
Tags
Los Angeles Times, LA Times, L. A. Times
Sign in or sign up to post comments.
Be the first to comment